Literature DB >> 3675670

Synthesis and antitumor activity of triazolium-bis(triazole)-tetrachlororuthenate (III) and bistriazolium-triazolepentachlororuthenate (III). Two representatives of a new class of inorganic antitumor agents.

B K Keppler1, W Balzer, V Seifried.   

Abstract

The synthesis of the two water-soluble heterocycle coordinated ruthenium complexes triazolium-bis(triazole) tetrachlororuthenate (III), TrH(RuTr2Cl4), and bistriazolium-triazolepentachlororuthenate (III), (TrH)2(RuTrCl5), is described. For these complexes, antitumor activity against the P 388 leukemia model was observed with T/C values of 137% to 150%, compared with 144% and 175% for 5-fluorouracil and cisplatin, respectively. These complexes belong to a new class of antitumor active ruthenium compounds with the general formulas HB(RuB2Cl4) and (HB) 2(RuBCl5). The here described complexes with B = triazole are less active than the same type of complexes with B = imidazole, which were described by us previously.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3675670

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.

Authors:  Cynthia Licona; Marie-Elodie Spaety; Antonelle Capuozzo; Moussa Ali; Rita Santamaria; Olivier Armant; Francois Delalande; Alain Van Dorsselaer; Sarah Cianferani; John Spencer; Michel Pfeffer; Georg Mellitzer; Christian Gaiddon
Journal:  Oncotarget       Date:  2017-01-10

2.  In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.

Authors:  R E Aird; J Cummings; A A Ritchie; M Muir; R E Morris; H Chen; P J Sadler; D I Jodrell
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.